Baxter faces class action lawsuit amid product defects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy BAX?
Source: Globenewswire
Baxter International Inc (BAX) saw a price increase of 3.00%, reaching a 20-day high. This movement occurs amid broader market weakness, with the Nasdaq-100 down 0.27% and the S&P 500 down 0.13%.
The stock's rise comes despite significant legal challenges, as Baxter is facing a class action lawsuit over systemic defects in its Novum LVP devices. The lawsuit alleges that these defects pose serious risks to patients, potentially leading to severe consequences for the company's sales and reputation. Investors are concerned about the implications of this lawsuit, which could lead to increased regulatory scrutiny and legal liabilities for Baxter.
The ongoing legal issues may overshadow the stock's recent performance, indicating that while the price has risen, investor sentiment remains cautious due to the potential financial and reputational impacts of the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 21.870
Low
15.00
Averages
22.13
High
30.00
Current: 21.870
Low
15.00
Averages
22.13
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pale Fire Capital Acquires Baxter Shares Worth $39.63 Million
- New Stake Acquisition: Pale Fire Capital disclosed in its SEC filing dated February 13, 2026, that it acquired 2,074,016 shares of Baxter International, with an estimated trade value of $39.63 million, indicating a strong confidence in the healthcare sector.
- Position Value Change: At quarter-end, Baxter's position was valued at $39.63 million, reflecting the dual impact of new share acquisitions and stock price movements, further solidifying its place in the investment portfolio.
- Portfolio Restructuring: Pale Fire Capital significantly increased its investment in healthcare stocks during the fourth quarter, with Baxter being the largest new stock addition, demonstrating a strategic pivot towards the healthcare industry.
- Sales Growth Potential: Despite reporting significant net losses in 2024 and 2025, Baxter's fourth-quarter sales rose by 8% year-over-year, particularly strong in international markets, indicating potential for future recovery.
See More
Pale Fire Capital Acquires Baxter International Shares
- New Investment Dynamics: According to its latest SEC filing dated February 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International (BAX) by purchasing 2,074,016 shares, with an estimated transaction value of $39.63 million, reflecting confidence in the healthcare sector.
- Asset Allocation Shift: Baxter's shares account for 2.66% of Pale Fire Capital SE's $1.49 billion reportable U.S. equity AUM as of December 31, 2025, indicating a strategic focus on healthcare investments by the fund.
- Market Performance Analysis: As of February 13, 2026, Baxter's stock price stood at $19.79, down 34.2% year-over-year, significantly underperforming the S&P 500 by 46 percentage points, suggesting market caution regarding its future growth prospects.
- Financial Overview: Baxter reported $11.24 billion in trailing twelve-month revenue and a net loss of $900 million; however, the 8% growth in fourth-quarter sales from continuing operations, particularly in international markets, indicates potential recovery signs.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
Baxter International Shares Plunge 17% Following Lackluster Earnings Report
- Disappointing Earnings: Baxter International's Q4 2025 sales rose 8% year-over-year to $2.97 billion, yet its non-GAAP net income plummeted 24% to $225 million ($0.44 per share), failing to meet analysts' expectations of $0.54 per share, resulting in a 17% drop in stock price during trading.
- Market Reaction: The disappointing earnings report led to a significant decline in Baxter's stock price, which currently stands at $18.79, with a market cap of $11 billion, indicating investor concerns regarding the company's future performance.
- Bleak Outlook: Baxter forecasts flat to 1% sales growth for 2026, with adjusted net income projected at $1.85 to $2.05 per share, down from $2.27 in 2025, highlighting the challenges and uncertainties the company faces moving forward.
- Strategic Transition Risks: Although Baxter has pledged to enhance customer relationships and execution through a new operating model, investor skepticism about the long-term effectiveness of this transition may undermine shareholder confidence and future investment decisions.
See More
Baxter International Q4 2025 Earnings Call Insights
- Sales Growth Overview: In Q4 2025, Baxter International reported global sales of $3 billion, an 8% increase year-over-year, but adjusted EPS of $0.44 fell short of expectations, indicating pressure from sales mix and nonrecurring items.
- Early Turnaround Efforts: CEO Andrew Hider emphasized that the company is in the early stages of a turnaround, streamlining its organizational structure to enhance accountability, which is expected to drive long-term performance improvements, although this will take time.
- Cautious Future Outlook: Baxter anticipates total sales growth for 2026 to be flat to 1%, with adjusted EPS projected between $1.85 and $2.05, reflecting a cautious stance towards foreign exchange fluctuations and market conditions.
- Strong Cash Flow Performance: Free cash flow exceeded $450 million in Q4, with total free cash flow for the year reaching $438 million, demonstrating robust cash management despite margin pressures.
See More
Wall Street Rattled by Cisco's Cautious Outlook
- Cisco's Stock Plunge: Despite beating earnings and revenue expectations, Cisco Systems Inc. (NASDAQ:CSCO) saw its shares drop over 11%, marking the worst single-day decline since May 2022, as investors expressed concerns over profit durability.
- Tech Sector Decline: The iShares Tech-Expanded Software Sector ETF (NYSE:IGV) fell 3.7%, revisiting lows from last week, indicating heightened sensitivity to AI disruption risks following Cisco's outlook.
- Small Caps Underperform: The Nasdaq 100 dropped 1.7%, while both the S&P 500 and Dow Jones Industrial Average lost 1.2%, with the Russell 2000 small-cap index sliding 2.4%, reflecting a cautious market sentiment.
- Increased Volatility: The VIX surged 16%, as investors rotated into defensive sectors, with utilities and consumer staples outperforming, highlighting a risk-off tone in the market.
See More
Pale Fire Capital Acquires Baxter Shares Worth $39.63 Million
- New Stake Acquisition: Pale Fire Capital disclosed in its SEC filing dated February 13, 2026, that it acquired 2,074,016 shares of Baxter International, with an estimated trade value of $39.63 million, indicating a strong confidence in the healthcare sector.
- Position Value Change: At quarter-end, Baxter's position was valued at $39.63 million, reflecting the dual impact of new share acquisitions and stock price movements, further solidifying its place in the investment portfolio.
- Portfolio Restructuring: Pale Fire Capital significantly increased its investment in healthcare stocks during the fourth quarter, with Baxter being the largest new stock addition, demonstrating a strategic pivot towards the healthcare industry.
- Sales Growth Potential: Despite reporting significant net losses in 2024 and 2025, Baxter's fourth-quarter sales rose by 8% year-over-year, particularly strong in international markets, indicating potential for future recovery.
See More
Pale Fire Capital Acquires Baxter International Shares
- New Investment Dynamics: According to its latest SEC filing dated February 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International (BAX) by purchasing 2,074,016 shares, with an estimated transaction value of $39.63 million, reflecting confidence in the healthcare sector.
- Asset Allocation Shift: Baxter's shares account for 2.66% of Pale Fire Capital SE's $1.49 billion reportable U.S. equity AUM as of December 31, 2025, indicating a strategic focus on healthcare investments by the fund.
- Market Performance Analysis: As of February 13, 2026, Baxter's stock price stood at $19.79, down 34.2% year-over-year, significantly underperforming the S&P 500 by 46 percentage points, suggesting market caution regarding its future growth prospects.
- Financial Overview: Baxter reported $11.24 billion in trailing twelve-month revenue and a net loss of $900 million; however, the 8% growth in fourth-quarter sales from continuing operations, particularly in international markets, indicates potential recovery signs.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
Baxter International Shares Plunge 17% Following Lackluster Earnings Report
- Disappointing Earnings: Baxter International's Q4 2025 sales rose 8% year-over-year to $2.97 billion, yet its non-GAAP net income plummeted 24% to $225 million ($0.44 per share), failing to meet analysts' expectations of $0.54 per share, resulting in a 17% drop in stock price during trading.
- Market Reaction: The disappointing earnings report led to a significant decline in Baxter's stock price, which currently stands at $18.79, with a market cap of $11 billion, indicating investor concerns regarding the company's future performance.
- Bleak Outlook: Baxter forecasts flat to 1% sales growth for 2026, with adjusted net income projected at $1.85 to $2.05 per share, down from $2.27 in 2025, highlighting the challenges and uncertainties the company faces moving forward.
- Strategic Transition Risks: Although Baxter has pledged to enhance customer relationships and execution through a new operating model, investor skepticism about the long-term effectiveness of this transition may undermine shareholder confidence and future investment decisions.
See More
Baxter International Q4 2025 Earnings Call Insights
- Sales Growth Overview: In Q4 2025, Baxter International reported global sales of $3 billion, an 8% increase year-over-year, but adjusted EPS of $0.44 fell short of expectations, indicating pressure from sales mix and nonrecurring items.
- Early Turnaround Efforts: CEO Andrew Hider emphasized that the company is in the early stages of a turnaround, streamlining its organizational structure to enhance accountability, which is expected to drive long-term performance improvements, although this will take time.
- Cautious Future Outlook: Baxter anticipates total sales growth for 2026 to be flat to 1%, with adjusted EPS projected between $1.85 and $2.05, reflecting a cautious stance towards foreign exchange fluctuations and market conditions.
- Strong Cash Flow Performance: Free cash flow exceeded $450 million in Q4, with total free cash flow for the year reaching $438 million, demonstrating robust cash management despite margin pressures.
See More
Wall Street Rattled by Cisco's Cautious Outlook
- Cisco's Stock Plunge: Despite beating earnings and revenue expectations, Cisco Systems Inc. (NASDAQ:CSCO) saw its shares drop over 11%, marking the worst single-day decline since May 2022, as investors expressed concerns over profit durability.
- Tech Sector Decline: The iShares Tech-Expanded Software Sector ETF (NYSE:IGV) fell 3.7%, revisiting lows from last week, indicating heightened sensitivity to AI disruption risks following Cisco's outlook.
- Small Caps Underperform: The Nasdaq 100 dropped 1.7%, while both the S&P 500 and Dow Jones Industrial Average lost 1.2%, with the Russell 2000 small-cap index sliding 2.4%, reflecting a cautious market sentiment.
- Increased Volatility: The VIX surged 16%, as investors rotated into defensive sectors, with utilities and consumer staples outperforming, highlighting a risk-off tone in the market.
See More
